Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 6/2021

01.06.2021 | Orthopedic Oncology (JA Abraham, Section Editor)

Update on Osteosarcoma

verfasst von: Rebekah Belayneh, Mitchell S. Fourman, Sumail Bhogal, Kurt R. Weiss

Erschienen in: Current Oncology Reports | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Osteosarcoma (OSA) is the most common primary tumor of bone, mainly affecting children and adolescents. Here we discuss recent advances in surgical and systemic therapies, and highlight potentially new modalities in preclinical evaluation and prognostication.

Recent Findings

The advent of neoadjuvant and adjuvant chemotherapy has markedly improved the disease-free recurrence and overall survival of OSA. However, treatment efficacy has been stagnant since the 1980s. This plateau has prompted preclinical and clinical research into in precision surgery, inhaled chemotherapy to increase pulmonary drug concentration without systemic side effects, and novel immunomodulators intended to block molecular pathways associated with OSA proliferation and metastasis.

Summary

With the advent of novel surgical techniques and new forms and vectors for chemotherapy, it is hoped that OSA treatment outcomes will exceed their currently sustained plateau in the near future.
Literatur
1.
Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am. 2000;82:667–74.PubMed
2.
Cho WH, Song WS, Jeon D-G, Kong C-B, Kim MS, Lee JA, et al. Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations. Ann Surg Oncol. 2010;17:702–8.PubMed
3.
Abate ME, Longhi A, Galletti S, Ferrari S, Bacci G. Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger. Pediatr Blood Cancer. 2010;55:652–4.PubMed
4.
Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–8.PubMed
5.
Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JAM, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer. 2009;45:2367–75.PubMed
6.
Gross SW. The classic: sarcoma of the long bones: based upon a study of one hundred and sixty-five cases. 1879. Clin Orthop Relat Res. 2005;438:9–14.PubMed
7.
Broström LA, Strander H, Nilsonne U. Survival in osteosarcoma in relation to tumor size and location. Clin Orthop Relat Res 1982;250–254.
8.
Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ. Trends and variability in survival from osteosarcoma. Mayo Clin Proc. 1978;53:695–700.PubMed
9.
Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol. 1972;4:482–510.PubMed
10.
Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am. 1967;49:101–10.PubMed
11.
Jaffe N. The classic: recent advances in chemotherapy of metastatic osteogenic sarcoma. 1972. Clin Orthop Relat Res. 2005;438:19–21.PubMed
12.
Sutow WW, Sullivan MP, Fernbach DJ, Cangir A, George SL. Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study. Cancer. 1975;36:1598–602.PubMed
13.
Sutow WW, Sullivan MP, Wilbur JR, Cangir A. Study of adjuvant chemotherapy in osteogenic sarcoma. J Clin Pharmacol. 1975;15:530–3.PubMed
14.
Cortes EP, Holland JF, Wang JJ, Sinks LF, Blom J, Senn H, et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med. 1974;291:998–1000.PubMed
15.
Sutow WW. Multidrug chemotherapy in osteosarcoma. Clin Orthop Relat Res. 1980:67–72.
16.
Goorin AM, Perez-Atayde A, Gebhardt M, Andersen JW, Wilkinson RH, Delorey MJ, et al. Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children’s Hospital--study III. J Clin Oncol. 1987;5:1178–84.PubMed
17.
Edmonson JH, Green SJ, Ivins JC, Gilchrist GS, Creagan ET, Pritchard DJ, et al. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol. 1984;2:152–6.PubMed
18.
Edmonson JH, Green SJ, Ivins JC, Gilchrist GS, Cregan ET, Pritchard DJ, et al. Methotrexate as adjuvant treatment for primary osteosarcoma. N Engl J Med. 1980;303:642–3.PubMed
19.
Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600–6.PubMed
20.
Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5:21–6.PubMed
21.
Simpson E, Brown HL. Understanding osteosarcomas. JAAPA. 2018;31:15–9.PubMed
22.
Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012;118:5888–93.PubMed
23.
Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976;37:1–11.PubMed
24.
Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–30.PubMed
25.
Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–27.PubMed
26.
Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A, et al. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg (Br). 2002;84:88–92.
27.
Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–35.PubMedPubMedCentral
28.
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.PubMed
29.
Bielack S, Jürgens H, Jundt G, Kevric M, Kühne T, Reichardt P, et al. Osteosarcoma: the COSAS experience. Cancer Treat Res. 2009;152:289–308.PubMed
30.
Ferrari S, Serra M. An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 2015;16:2727–36.PubMed
31.
Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:633–8.PubMed
32.
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative map: first results of the EURAMOSA-1 good response randomized controlled trial. J Clin Oncol. 2015;33:2279–87.PubMedPubMedCentral
33.
Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voûte PA, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579–91.PubMed
34.
Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911–7.PubMed
35.
Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OSA-1. J Clin Oncol. 2012;30:2112–8.PubMed
36.
Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res. 2014;162:65–92.PubMed
37.
Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5–15.PubMed
38.
Whelan JS, Davis LE. Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 2018;36:188–93.PubMed
39.
40.
41.
DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 2005;61:492–8.PubMed
42.
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.PubMedPubMedCentral
43.
Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL. Osteosarcoma: a meta-analysis and review of the literature. Am J Orthop. 2015;44:547–53.PubMed
44.
Okada K, Frassica FJ, Sim FH, Beabout JW, Bond JR, Unni KK. Parosteal osteosarcoma. A clinicopathological study. J. Bone Joint Surg. Am. 1994;76:366–78.
45.
Grimer RJ, Bielack S, Flege S, Cannon SR, Foleras G, Andreeff I, et al. Periosteal osteosarcoma--a European review of outcome. Eur J Cancer. 2005;41:2806–11.PubMed
46.
Rose PS, Dickey ID, Wenger DE, Unni KK, Sim FH. Periosteal osteosarcoma: long-term outcome and risk of late recurrence. Clin Orthop Relat Res. 2006;453:314–7.PubMed
47.
48.
Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–61.PubMed
49.
Szendroi M, Pápai Z, Koós R, Illés T. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. J Surg Oncol. 2000;73:87–94.PubMed
50.
Ruggieri P, Calabrò T, Montalti M, Mercuri M. The role of surgery and adjuvants to survival in Pagetic osteosarcoma. Clin Orthop Relat Res. 2010;468:2962–8.PubMedPubMedCentral
51.
Iwata S, Ishii T, Kawai A, Hiruma T, Yonemoto T, Kamoda H, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol. 2014;21:263–8.PubMed
52.
Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–41.PubMed
53.
Hendershot E, Pappo A, Malkin D, Sung L. Tumor necrosis in pediatric osteosarcoma: impact of modern therapies. J Pediatr Oncol Nurs. 2006;23:176–81.PubMed
54.
Zelken JA, Tufaro AP. Current trends and emerging future of indocyanine green usage in surgery and oncology: an update. Ann Surg Oncol. 2015;22(Suppl 3):S1271–83.PubMed
55.
Fourman MS, McKenna P, Phillips BT, Crawford L, Romanelli F, Lin F, et al. ICG angiography predicts burn scarring within 48 h of injury in a porcine vertical progression burn model. Burns. 2015;41:1043–8.PubMed
56.
•• Fourman MS, Mahjoub A, Mandell JB, Yu S, Tebbets JC, Crasto JA, et al. Quantitative primary tumor indocyanine green measurements predict osteosarcoma metastatic lung burden in a mouse model. Clin Orthop Relat Res. 2018;476:479–87. This paper describes a novel way of quantifying primary and metastatic osteosarcoma tumors in a previously validated immunocompetent orthotopic mouse model. The potential utility of indocyanine green as an intraoperative margin and tumor detector as opposed to intraoperative histology makes it a very valuable clinical tool for debulking procedures in anatomically vulnerable locations.PubMedPubMedCentral
57.
•• Mahjoub A, Morales-Restrepo A, Fourman MS, Mandell JB, Feiqi L, Hankins ML, et al. Tumor resection guided by intraoperative indocyanine green dye fluorescence angiography results in negative surgical margins and decreased local recurrence in an orthotopic mouse model of osteosarcoma. Ann Surg Oncol. 2019;26:894–8. This paper demonstrates that using intraoperative indocyanine green dye fluorescence angiography is an extremely effective tool in achieving negative surgical margins and, in turn, diminishes the chance of local recurrence in mice with osteosarcoma. This is a tool that has huge potential in the clinical realm.PubMed
58.
59.
Mao Y, Chi C, Yang F, Zhou J, He K, Li H, et al. The identification of sub-centimetre nodules by near-infrared fluorescence thoracoscopic systems in pulmonary resection surgeries. Eur J Cardiothorac Surg. 2017;52:1190–6.PubMed
60.
Zhou H, Yi W, Li A, Wang B, Ding Q, Xue L, et al. Specific small-molecule NIR-II fluorescence imaging of osteosarcoma and lung metastasis. Adv Healthc Mater. 2020;9:e1901224.PubMed
61.
Sakuda T, Kubo T, Johan MP, Furuta T, Sakaguchi T, Nakanishi M, et al. Novel near-infrared fluorescence-guided surgery with vesicular stomatitis virus for complete surgical resection of osteosarcomas in mice. J Orthop Res. 2019;37:1192–201.PubMed
62.
Cheng J, Wang W, Xu X, Lin Z, Xie C, Zhang Y, et al. AgBiS2 nanoparticles with synergistic photodynamic and bioimaging properties for enhanced malignant tumor phototherapy. Mater Sci Eng C Mater Biol Appl. 2020;107:110324.PubMed
63.
Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. J Clin Oncol. 2001;19:1839–47.PubMed
64.
Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res. 2001;7:3258–62.PubMed
65.
Kiany S, Gordon N. Aerosol delivery of interleukin-2 in combination with adoptive transfer of natural killer cells for the treatment of lung metastasis: methodology and effect. Methods Mol Biol. 2016;1441:285–95.PubMed
66.
•• Gordon N, Felix K, Daw NC. Aerosolized chemotherapy for osteosarcoma. Adv Exp Med Biol. 2020;1257:67–73. Pulmonary metastasis of osteosarcoma is a major contributor to poorer prognosis and is difficult to treat. Aerosol chemotherapy has been proven to be effective in causing regression of pulmonary metastases and improving survival in mice with osteosarcoma. This chapter reviews various chemotherapeutic agents delivered via inhalation therapy and ongoing studies in patients with lung metastases with aerosolized chemotherapy.PubMed
67.
Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weigel B, et al. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015;62:1562–6.PubMedPubMedCentral
68.
Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Bertulli R, Asaftei SD, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16:98–107.PubMed
69.
•• Regan DP, Coy JW, Chahal KK, Chow L, Kurihara JN, Guth AM, Kufareva I, Dow SW, The angiotensin receptor blocker losartan suppresses growth of pulmonary metastases via AT1R-independent inhibition of CCR2 signaling and monocyte recruitment. J Immunol. 2019;202(10):3087–102. Pazopanib, a selective multitargeted tyrosine kinase inhibitor that has been proven to be effective in the treatment of metastatic soft tissue sarcomas, was evaluated in this study in the treatment of metastatic bone sarcomas in patients who failed chemotherapy. This study demonstrated that pazopanib is a well-tolerated and effective treatment of metastatic bone sarcomas refractory to traditional chemotherapy. Given the poor prognosis associated with metastatic, chemotherapy-resistant, bone sarcomas, identification of effective treatment alternatives is of utmost importance.
70.
Coens C, van der Graaf WTA, Blay J-Y, Chawla SP, Judson I, Sanfilippo R, et al. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Cancer. 2015;121:2933–41.PubMed
71.
Safwat A, Boysen A, Lücke A, Rossen P. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients. Acta Oncol (Madr). 2014;53:1451–4.
72.
Umeda K, Kato I, Saida S, Okamoto T, Adachi S. Pazopanib for second recurrence of osteosarcoma in pediatric patients. Pediatr Int. 2017;59:937–8.PubMed
73.
Longhi A, Paioli A, Palmerini E, Cesari M, Abate ME, Setola E, et al. Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta Oncol. 2019;58:124–8.PubMed
74.
75.
•• Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:446–55. This clinical trial demonstrates the antitumor effect and drug-related adverse events of cabozantinib, a new therapeutic option for osteosarcoma treatment.PubMed
76.
Koonrungsesomboon N, Ngamphaiboon N, Townamchai N, Teeyakasem P, Charoentum C, Charoenkwan P, et al. Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of mycophenolate mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial. BMC Cancer. 2020;20:268.PubMedPubMedCentral
77.
•• Klangjorhor J, Chaiyawat P, Teeyakasem P, Sirikaew N, Phanphaisarn A, Settakorn J, et al. Mycophenolic acid is a drug with the potential to be repurposed for suppressing tumor growth and metastasis in osteosarcoma treatment. Int J Cancer. 2020;146:3397–409. This paper demonstrates the in vivo antitumor effect of mycophenolate mofetil, an immunosuppressive drug already used in humans in the treatment of autoimmune diseases or organ transplants. More specifically, mycophenolate mofetil significantly reduced the number of lung metastatic nodules compared to the vehicle group in mice. This could be a novel treatment targeting an aspect of osteosarcoma that portends a poor prognosis, metastases.PubMed
78.
Yamagishi T, Kawashima H, Ogose A, Ariizumi T, Sasaki T, Hatano H, et al. Receptor-activator of nuclear kappaB ligand expression as a new therapeutic target in primary bone tumors. PLoS One. 2016;11:e0154680.PubMedPubMedCentral
79.
Ohba T, Cates JMM, Cole HA, Slosky DA, Haro H, Ichikawa J, et al. Pleiotropic effects of bisphosphonates on osteosarcoma. Bone. 2014;63:110–20.PubMed
80.
Beristain AG, Narala SR, Di Grappa MA, Khokha R. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci. 2012;125:943–55.PubMed
81.
Savvidou OD, Bolia IK, Chloros GD, Papanastasiou J, Koutsouradis P, Papagelopoulos PJ. Denosumab: current use in the treatment of primary bone tumors. Orthopedics. 2017;40:204–10.PubMed
82.
83.
Ouyang Z, Li H, Zhai Z, Xu J, Dass CR, Qin A, et al. Zoledronic acid: pleiotropic anti-tumor mechanism and therapeutic outlook for osteosarcoma. Curr Drug Targets. 2018;19:409–21.PubMed
84.
Piperno-Neumann S, Le Deley M-C, Rédini F, Pacquement H, Marec-Bérard P, Petit P, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17:1070–80.PubMed
85.
•• Tsuda Y, Tsoi K, Stevenson JD, Parry MC, Fujiwara T, Sumathi V, et al. Is microscopic vascular invasion in tumor specimens associated with worse prognosis in patients with high-grade localized osteosarcoma? Clin Orthop Relat Res. 2020;478:1190–8. This paper examines microscopic vascular invasion (MVI) as a prognostic factor in high-grade localized osteosarcoma. Finding that MVI is associated with lower overall survival and higher cumulative incidence of local recurrence or metastasis, this measurement has huge potential to be used in the future in new clinical trials and as a novel prognostic factor in patients with osteosarcoma.PubMed
86.
Anderson ME, Wu JS, Vargas SO. CORR® tumor board: is microscopic vascular invasion in tumor specimens associated with worse prognosis in patients with high-grade localized osteosarcoma? Clin Orthop Relat Res. 2020;478:1186–9.PubMed
87.
Dobrenkov K, Ostrovnaya I, Gu J, Cheung IY, Cheung N-KV. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer. 2016;63:1780–5.PubMedPubMedCentral
88.
Doronin II, Vishnyakova PA, Kholodenko IV, Ponomarev ED, Ryazantsev DY, Molotkovskaya IM, et al. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer. 2014;14:295.PubMedPubMedCentral
89.
Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050–6.PubMedPubMedCentral
90.
Poon VI, Roth M, Piperdi S, Geller D, Gill J, Rudzinski ER, et al. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clin Sarcoma Res. 2015;5:4.PubMedPubMedCentral
91.
Bishop MW, Hutson PR, Hank JA, Sondel PM, Furman WL, Meagher MM, et al. A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors. MAbs. 2020;12:1773751.PubMedPubMedCentral
92.
Greco N, Schott T, Mu X, Rothenberg A, Voigt C, McGough RL, et al. ALDH activity correlates with metastatic potential in primary sarcomas of bone. J Cancer Ther. 2014;5:331–8.PubMedPubMedCentral
93.
Mu X, Isaac C, Schott T, Huard J, Weiss K. Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells. Sarcoma. 2013;2013:480713.PubMedPubMedCentral
94.
95.
Cho H-J, Lee T-S, Park J-B, Park K-K, Choe J-Y, Sin D-I, et al. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol. 2007;40:1069–76.PubMed
96.
Crasto JA, Fourman MS, Morales-Restrepo A, Mahjoub A, Mandell JB, Ramnath K, et al. Disulfiram reduces metastatic osteosarcoma tumor burden in an immunocompetent Balb/c or-thotopic mouse model. Oncotarget. 2018;9:30163–72.PubMedPubMedCentral
97.
•• Mandell JB, Lu F, Fisch M, Beumer JH, Guo J, Watters RJ, et al. Combination therapy with disulfiram, copper, and doxorubicin for osteosarcoma: in vitro support for a novel drug repurposing strategy. Sarcoma. 2019;2019:1320201. This paper is a comprehensive investigation on copper in osteosarcoma. Beyond examining differences in endogenous copper level and copper transporter genes in murine osteosarcoma cells with differing metastatic potentials, this study also demonstrated the ability of copper chloride to augment the efficacy of disulfiram in sarcoma treatment.PubMedPubMedCentral
98.
Denoyer D, Masaldan S, La Fontaine S, Cater MA. Targeting copper in cancer therapy: “Copper That Cancer”. Metallomics. 2015;7:1459–76.PubMed
99.
•• Wang Y, Yu W, Zhu J, Wang J, Xia K, Liang C, et al. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J Exp Clin Cancer Res. 2019;38:168. Considering the urgent need for new therapeutic regiments, this paper features an effective novel immunological treatment strategy in the future clinical practice for the treatment of osteosarcoma: chimeric antigen receptor (CAR)–engineered T cells.PubMedPubMedCentral
100.
Metadaten
Titel
Update on Osteosarcoma
verfasst von
Rebekah Belayneh
Mitchell S. Fourman
Sumail Bhogal
Kurt R. Weiss
Publikationsdatum
01.06.2021
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 6/2021
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01053-7

Weitere Artikel der Ausgabe 6/2021

Current Oncology Reports 6/2021 Zur Ausgabe

Neuroendocrine Neoplasms (NS Reed, Section Editor)

Update on Histological Reporting Changes in Neuroendocrine Neoplasms

Interventional Oncology (DC Madoff, Section Editor)

Role of Machine Learning and Artificial Intelligence in Interventional Oncology

Interventional Oncology (DC Madoff, Section Editor)

Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy

Leukemia (A Aguayo, Section Editor)

Extracellular vesicles and their associated miRNAs as potential prognostic biomarkers in chronic lymphocytic leukemia

Integrative Care (C Lammersfeld, Section Editor)

Integrative Approaches to Minimize Peri-operative Symptoms

Breast Cancer (AS Zimmer, Section Editor)

Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise